Effects of the Wenyang Zhenshuai Granule on the Expression of LncRNA-MiR143HG/miR-143 Regulating ERK5 in H9C2 Cardiomyocytes

Zelin Xu, Xinyu Chen, Qingyang Chen, and Huzhi Cai

The First Hospital of Hunan University of Chinese Medicine, Changsha 410007, Hunan, China

Correspondence should be addressed to Huzhi Cai; chz_hntcm@163.com

Received 15 July 2021; Accepted 29 July 2021; Published 9 August 2021

Academic Editor: Songwen Tan

Chronic heart failure (CHF) is a complex clinical syndrome caused by a variety of heart problems, with a high incidence. The 5-year survival rate of patients with clinical symptoms is similar to that of malignant tumors [1–3]. The previous research of the research group confirmed that the phosphorylation expression of ERK5 pathway protein, the main subfamily of mitogen-activated protein kinase (MAPK) signaling pathway, is closely and negatively correlated with the progression of CHF [4], and Wenyang Zhenshuai Granules can significantly upregulate the expression of ERK5 protein phosphorylation. Bioinformatics analysis shows that the 3′UTR of human ERK5 gene contains a putative consensus site (nucleotides 2917–2932) bound by microRNA-143 (miRNA-143) [5], and it is based on the luciferase reporter gene vector. The experiment verified the specificity of miR-143 and ERK5 in sequence binding and confirmed that there is a theoretical basis for interaction [6–8]. As the host gene of miR-143, long noncoding RNA-MiR143HG (LncRNA-MiR143HG) has been proven to directly regulate miR-143, and the regulation between the two plays an important role in the process of heart development and structure formation [9]. Through further research, we found that the specific role of the LncRNA-MiR143HG/miR-143/ERK5 regulatory system in the occurrence and development of chronic heart failure is still unclear. Whether Wenyang Zhenshuai granules regulates LncRNA-MiR143HG/miR-143/ERK5 in sequence binding and confirmed that there is a theoretical basis for interaction [6–8]. As the host gene of miR-143, long noncoding RNA-MiR143HG (LncRNA-MiR143HG) has been proven to directly regulate miR-143, and the regulation between the two plays an important role in the process of heart development and structure formation [9]. Through further research, we found that the specific role of the LncRNA-MiR143HG/miR-143/ERK5 regulatory system in the occurrence and development of chronic heart failure is still unclear. Whether Wenyang Zhenshuai granules regulates LncRNA-MiR143HG/miR-143. In turn, it affects the ERK5-mediated cardiomyocyte damage effect and produces a therapeutic effect. In order to answer this scientific question, we designed and completed this experiment.

1. Introduction

Chronic heart failure (CHF) is a complex clinical syndrome caused by the progression of various heart diseases to severe stages. Its incidence is high. The 5-year survival rate of patients with clinical symptoms is similar to that of malignant tumors [1–3]. The previous research of the research group confirmed that the phosphorylation expression of ERK5 pathway protein, the main subfamily of mitogen-activated protein kinase (MAPK) signaling pathway, is closely and negatively correlated with the progression of CHF [4], and Wenyang Zhenshuai Granules can significantly upregulate the expression of ERK5 protein phosphorylation. Bioinformatics analysis shows that the 3′UTR of human ERK5 gene contains a putative consensus site (nucleotides 2917–2932) bound by microRNA-143 (miRNA-143) [5], and
2. Materials and Methods

2.1. Drugs and Reagents. Adriamycin hydrochloride was provided by Shenzhen Wanle Pharmaceutical Co., Ltd. (H44024359), SYBR Green PCR kit was purchased from Shanghai Sixin Biotechnology Co., Ltd. (BL705A), and Wenyang Zhenshui granules were purchased from the First Affiliated Hospital of Hunan University of Traditional Chinese Medicine Provided (201902), and ERK5 and p-ERK5 antibodies were purchased from Wuhan Boster Bioengineering Co., Ltd. (ab40908, ab5686). LncRNA-MiR143HG overexpression and siRNA vector were purchased from Shanghai Ebers Biotechnology Co., Ltd.

2.2. Subculture of Cardiomyocyte Cell Lines. H9C2 cardiomyocytes (Shanghai Gefan Biological Cell Bank) were used, and the cells were passaged in DMEM medium with 10% FBS. When the cells became full at the bottom of the culture flask, 0.25% trypsin was added and the adherent cells were gently pipetted to make a single cell solution; the remaining cell suspension was diluted and then the cell count was performed, and the cell concentration was adjusted according to the counting result and planted in a plate for culture.

2.3. Preparation of Medicated Serum. We used distilled water to make 6 ml solution of Wenyang Zhenshui granules (1.44 g/kg·d) into rats [4], gavage twice a day, 3 ml each time for 7 days; 7 days later, blood was taken from the abdominal aorta. The blood was centrifuged at 3000 r/min, the supernatant was taken, and the bacteria were removed by suction filtration, then aliquoted, stored in a refrigerator at −20°C for later use, and configured to be used at a concentration of 10% for experiments.

2.4. Transfection of LncRNA-MiR143HG Overexpression and Silence in Cardiomyocytes. 1×10^5 cells were seeded in a 6-well plate, and 10% FBS-containing medium was added to the culture. When the cell density reached 50%, the transfection was started. LncRNA-MiR143HG overexpression and siRNA vector were diluted with pure DMEM, mixed, and incubated at room temperature for 5 minutes to prepare a DNA and siRNA dilution. Lipo2000 was diluted in the corresponding amount of DMEM, allowed to stand for 5 minutes at room temperature, and incubated for 20 minutes at room temperature to form a transfection complex. The corresponding amount of the transfection complex was placed in an incubator and the medium was changed after 6 hours. After the culture was over, the expression of LncRNA-MiR143HG in cardiomyocytes after transfection was detected by RT-PCR to determine whether the overexpression and silent transfection were successful.

2.5. Induction of Cardiomyocyte Damage and Grouping. Adriamycin (ADR) was added to the cardiomyocyte culture medium of the ADR group, and the concentration was adjusted to 2.67 μmol/L and cultured for 44 hours [10]. The cardiomyocytes were seeded in 6-well plates, and a total of 7 plates were seeded. Cells of each plate were grouped; they were divided into 7 groups, namely, the normal control group, LncRNA-MiR143HG overexpression group, LncRNA-MiR143HG silence group, ADR group, ADR+medicated serum group, ADR+LncRNA-MiR143HG overexpression+medicated serogroup, and ADR+LncRNA-MiR143HG silence+medicated serogroup.

2.6. Morphological Observation and Survival Rate Detection of Cardiomyocytes. After the experiment, the cardiomyocytes of each group were taken, and the morphological changes of the cardiomyocytes of each group were observed with an inverted microscope. After the experiment was completed, the cardiomyocytes of each group were collected, the cell suspension concentration was adjusted, 20 μl/ml MTT solution was added to the medium, the cell supernatant after MTT culture was sucked, DMSO solution was added, and the culture plate was shaken on a shaker at low speed for 10 minutes, and the absorbance value of each group of cells was detected by enzyme-linked immunosorbent assay at 490 nm. The greater the absorbance value, the higher the survival rate.

2.7. Detection of LncRNA-MiR143HG, miR-143, and ERK5 Gene Expression in Cardiomyocytes. The cardiomyocytes of each group were taken out, and primers were designed according to the LncRNA-MiR143HG, miR-143, and ERK5 gene sequences in the NCBI gene bank. The total RNA was extracted by Trizol in one step and stored at −80°C. Fluorescence quantitative RT-PCR analysis of LncRNA-MiR143HG, miR-143, and ERK5 was performed in accordance with the PCR reaction kit instructions, and 2^−ΔΔCT was used to calculate the multiple relationship between the target gene expression of the experimental group and the control group: ΔΔCT = ΔCTexperimental group − ΔCTcontrol group; ΔCTexperimental group = CTtarget gene, experimental group − CTinternal reference gene, experimental group; ΔCTcontrol group = CTtarget gene, control group − CTinternal reference gene, control group. The primer design is shown in Table 1.

2.8. Detection of ERK5 and p-ERK5 Protein Expression in Cardiomyocytes. SDS buffer was added to 50 μg of total cardiomyocyte protein, and the cells were denatured at 100°C for 8 minutes with a constant current. The first 15 minutes were electrophoresed at 16 mA/gel, and then 32 mA/gel was electrophoresed to the bottom. The electroswitching mode set the current according to the film area of 0.8 mA/cm², and the film was transferred for 2 h. ERK5 (1:1000) total protein and p-ERK5 (1:1000) protein primary antibodies were added separately and kept at 4°C overnight. Enzyme-labeled secondary antibody was added and hybridized at room temperature for 2 hours. TBST was rinsed for 10 min × 3 times. ECL was used for exposure, followed by visualization, scanning, saving, and analysis.
2.9. Statistics Methods. All data were tested for normality and processed with SPSS17.0 statistical analysis software package. Measurement data were all expressed. Single-factor analysis of variance was used for comparison between groups of averages and groups. LSD method was used for homogeneous variances, and Tamhane’s T2 method was used for uneven variances. P < 0.05 indicates statistical difference.

3. Results

3.1. Morphological Observation of Myocardial Cells in Each Group. Under an inverted microscope, cardiomyocytes in the normal control group, LncRNA-MiR143HG overexpression group, and LncRNA-MiR143HG silence group were arranged neatly, in a regular spindle or polygonal shape, with a sense of three-dimensionality and refraction; in the ADR group, there were wrinkles shrinkage, cells appeared flat, gaps became larger, and volume became smaller. The degeneration of cardiomyocytes in the ADR+medicated serum group, ADR+LncRNA-MiR143HG overexpression+medicated serogroup, and ADR+LncRNA-MiR143HG silence+medicated serogroup was improved compared with the ADR group. Among them is ADR+LncRNA, The improvement of MiR143HG overexpression+medicated serogroup was the most obvious as shown in Figure 1.

3.2. Comparison of the Survival Rate of Cardiomyocytes in Each Group. After the experiment, the comparison of the survival rate of cardiomyocytes in each group showed that the survival rate of the normal control group, the LncRNA-MiR143HG overexpression group, and the LncRNA-MiR143HG silence group were similar, and the difference was not statistically significant (P > 0.05). Compared with the normal control group, the cell survival rate of ADR group, ADR+medicated serum group, ADR+LncRNA-MiR143HG overexpression+medicated serogroup, and ADR+LncRNA-MiR143HG silence+medicated serogroup was improved compared with the ADR group. The expression of LncRNA-MiR143HG overexpression+medicated serogroup was significantly decreased compared with the normal control group. The difference was statistically significant (P < 0.05).

Table 1: qRT-PCR primers.

| Primer sequence         | Forward (5'-3')        | Reverse (5'-3')       |
|-------------------------|------------------------|-----------------------|
| LncRNA-MiR143HG         | CAGCTCCCAGAACTGTCGCC   | CCTGCTCCCTTTTCACCATGTCC |
| miR-143                 | CGCCTGAGATGAAGACCTGTA  | CAGAGGGGTGTTTAGA       |
| ERK5                    | CAATGCGGAGACGGCCTC     | CTGAAATTCTCAGAGCCACAA |
| 5S                      | GCCATAGGGCTACCCCGGAA   | CCTACAGACCCCGTATCCCA  |
| GAPDH                   | ACAGCAACAGGGTGTTGGAC   | TTTGAGGGTGACCGGAACCTT |

3.3. Expression of LncRNA-MiR143HG, miR-143, and ERK5 Genes in Cardiomyocytes of Each Group. After the experiment, the expression of LncRNA-MiR143HG in myocardial cells of each group was compared. The expression of LncRNA-MiR143HG in the LncRNA-MiR143HG overexpression group was significantly higher than that in the normal control group. The expression of LncRNA-MiR143HG in the LncRNA-MiR143HG silence group was significantly lower than that of the normal control group, and the difference was statistically significant (P < 0.05). Compared with the normal control group, the expression of LncRNA-MiR143HG in ADR group, ADR+medicated serum group, ADR+LncRNA-MiR143HG overexpression+medicated serogroup, and ADR+LncRNA-MiR143HG silence+medicated serogroup was significantly decreased. The difference is statistically significant (P < 0.05). Compared with the ADR group and ADR+LncRNA-MiR143HG silence+medicated serogroup, the expression of LncRNA-MiR143HG in ADR+LncRNA-MiR143HG overexpression in the ADR+medicated serum group, ADR+LncRNA-MiR143HG overexpression+medicated serogroup increased, and the difference was statistically significant (P < 0.05). The expression of LncRNA-MiR143HG decreased in the ADR+LncRNA-MiR143HG silence+medicated serogroup compared with the ADR group, and the difference was statistically significant (P < 0.05) as shown in Figure 3.

After the experiment, the expressions of miR-143 genes in cardiomyocytes of each group were compared. The expression of miR-143 in the normal control group, LncRNA-MiR143HG overexpression group, and LncRNA-MiR143HG silence group were similar, and the difference was not statistically significant (P > 0.05). The ADR group, ADR+medicated serum group, ADR+LncRNA-MiR143HG overexpression+medicated serogroup, and ADR+LncRNA-MiR143HG silence+medicated serogroup were compared with the normal control group, and the expression of miR-143 in cells was obviously rising; the difference was statistically significant (P < 0.05). Compared with the ADR group and the ADR+LncRNA-MiR143HG silence+medicated serogroup, the ADR+medicated serum group and ADR+LncRNA-MiR143HG overexpression+medicated serogroup showed a decrease in the expression of miR-143. Compared with the ADR group, the expression of miR-143 in the +LncRNA-MiR143HG silence+medicated serogroup was significantly increased, and the difference was statistically significant (P < 0.05) as shown in Figure 4.

After the experiment, the expressions of ERK5 genes in cardiomyocytes of each group were compared. The expressions of ERK5 in the normal control group, LncRNA-
MiR143HG overexpression group, and LncRNA-MiR143HG silence group were similar, and the difference was not statistically significant ($P > 0.05$). The ADR group, ADR + medicated serum group, ADR + LncRNA-MiR143HG overexpression + medicated serogroup, and ADR + LncRNA-MiR143HG silence + medicated serogroup were compared with the normal control group; the cell ERK5 expression was significantly decreased. The differences are all statistically significant ($P < 0.05$). The ADR + medicated serum group and ADR + LncRNA-MiR143HG overexpression + medicated serogroup had increased cell ERK5 expression compared with the ADR group, and the difference was statistically significant ($P < 0.05$). Compared with the ADR + LncRNA-MiR143HG silence + medicated serogroup, the ADR + medicated serum group, and ADR + LncRNA-MiR143HG overexpression + medicated serogroup had higher cell ERK5 expression, and the difference was statistically significant ($P < 0.05$). There was no significant difference between the ADR + LncRNA-MiR143HG silence + medicated serogroup and the ADR group ($P > 0.05$) as shown in Figure 5.

3.4. Expression of p-ERK5 and ERK5 in Cardiomyocytes of Each Group. After the experiment, the expression of p-ERK5 and ERK5 in cardiomyocytes of each group showed that the expression of P-ERK5 and ERK5 protein in the

**Figure 1:** Morphological observation of cardiomyocytes in each group after the experiment ($\times 100$). (a) Normal control group, (b) LncRNA-MiR143HG overexpression group, (c) LncRNA-MiR143HG silence group, (d) ADR group, (e) ADR + medicated serum group, (f) ADR + LncRNA-MiR143HG overexpression + medicated serogroup, and (g) ADR + LncRNA-MiR143HG silence + medicated serogroup.

**Figure 2:** Comparison of the survival rate of cardiomyocytes in each group. Note: compared with the normal control group, $^*P < 0.05$; compared with the ADR group, $^#P < 0.05$; compared with the ADR + LncRNA-MiR143HG silence + medicated serogroup, $^{++}P < 0.05$.

**Figure 3:** Comparison of LncRNA-MiR143HG expression in cardiomyocytes of various groups. Note: compared with the normal control group, $^*P < 0.05$; compared with the ADR group, $^#P < 0.05$; compared with the ADR + LncRNA-MiR143HG silence + medicated serogroup, $^{++}P < 0.05$.
Relative expression of MiR-143
Relative expression of ERK5

Figure 4: Comparison of miR-143 expression in cardiomyocytes of various groups. Note: compared with the normal control group, \(^*P < 0.05\); compared with the ADR group, \(^#P < 0.05\); compared with the ADR+LncRNA-MiR143HG silence+medicated serogroup, \(^*P < 0.05\).

Figure 5: Comparison of ERK5 expression in cardiomyocytes of various groups. Note: compared with the normal control group, \(^*P < 0.05\); compared with the ADR group, \(^#P < 0.05\); compared with the ADR+LncRNA-MiR143HG silence+medicated serogroup, \(^*P < 0.05\).

normal control group, LncRNA-MiR143HG overexpression group, and LncRNA-MiR143HG silence group were equivalent, and the difference was not statistically significant \((P > 0.05)\). Compared with the normal control group, ADR group, ADR+medicated serum group, and ADR+LncRNA-MiR143HG silence+medicated serogroup, the expression of P-ERK5 and ERK5 protein in cells decreased significantly, and the difference was statistically significant \((P < 0.05)\). ADR+medicated serum group, ADR+LncRNA-MiR143HG overexpression+medicated serogroup, and ADR+LncRNA-MiR143HG silence+medicated serogroup were compared with ADR group; the expression of P-ERK5 and ERK5 protein in cells had risen, and the difference was statistically significant \((P < 0.05)\). Compared with the ADR+LncRNA-MiR143HG silence+medicated serogroup, the ADR+medicated serum group and ADR+LncRNA-MiR143HG overexpression+medicated serogroup had higher cell P-ERK5 protein expression, and the difference was statistically significant \((P < 0.05)\). The ADR+LncRNA-MiR143HG overexpression+medicated serogroup had higher cell ERK5 protein expression than the ADR+LncRNA-MiR143HG silence+medicated serogroup, and the difference was statistically significant \((P < 0.05)\); ADR+LncRNA-MiR143HG overexpression+medicated serogroup was compared with normal control group, and ERK5 protein expression was not statistically different \((P > 0.05)\) as shown in Figure 6.

4. Discussion

Cells are the basic structures that make up life, and changes in cell structure and function are based on a series of intracellular signal transduction. ERK5 is an atypical pathway in the MAPK family. It is mainly located in the cytoplasm. It receives signals from outside the cell and is activated by its upstream kinase MEK5. It can then be transferred to the nucleus to phosphorylate the transcription factor cardiomyocyte enhancer and regulate its transcription active [11, 12]. Since ERK5 was cloned for the first time by Zhou et al. [13] in 1995, it has been found to control a series of functions originally thought to be completed by ERK1/2, and it is clear that it is in oxidative stress, hypoxia, reactive oxygen species, and various mitoses. Under the original excitement, it plays an important role in maintaining the integrity of blood vessels and the development of the heart. A large number of documents have shown that the medicines of traditional Chinese medicine have good effects on treating heart failure and other diseases [14, 15]. Wenyang Zhenshui granules contain a variety of Chinese herbal medicine ingredients. From the previous research results of the research group, Wenyang Zhenshui granules not only can activate p-ERK5 but also have obvious and beneficial regulatory effects on the main downstream active components MEF-2 and CREB through the ERK5 pathway. miR-143 is located in the long arm of human chromosome 5, zone 3, and zone 2. Its function mainly affects the expression of related specific proteins by regulating the posttranscriptional level and inhibiting the translation of target genes. Through bioinformatics analysis and luciferase reporter gene vector
Figure 6: Comparison of the expression of p-ERK5 and ERK5 proteins in cardiomyocytes of each group. (a) Normal control group, (b) LncRNA-MiR143HG overexpression group, (c) LncRNA-MiR143HG silence group, (d) ADR group, (e) ADR + medicated serum group, (f) ADR + LncRNA-MiR143HG overexpression + medicated serogroup, and (g) ADR + LncRNA-MiR143HG silence + medicated serogroup. Compared with the normal control group, $^* P < 0.05$; compared with the ADR group, $^# P < 0.05$; compared with the ADR + LncRNA-MiR143HG silence + medicated serogroup, $^{+*} P < 0.05$. 
experiment verification, it is presumed that the direct target gene of miR-143 is ERK5 [16]. Zheng [7] et al. proved that upregulation of miR-143 can significantly reduce the expression of p-ERK5 and ERK5 in cells, while downregulation of miR-143 has the opposite effect. As the host gene of miR-143, LncRNA-MiR143HG can directly regulate miR-143 and thus affect the development and function of the heart [9], and studies have shown that LncRNA-MiR143HG is significantly upregulated during myocardial remodeling in patients with aortic stenosis. It is suggested that it is involved in the process of myocardial remodeling [17]. In view of the abovementioned preliminary research results, LncRNA-MiR143HG, which caused changes in the expression of p-ERK5 and ERK5, may regulate LncRNA-MiR143HG and miR-143 in turn affects the cardiomyocyte protection mediated by ERK5.

5. Conclusion

In summary, Wenyang Zhenshui granules can down-regulate the expression of miR-143 to promote ERK5 protein expression and phosphorylation, and the related process is regulated by LncRNA-MiR143HG/miR-143, which may be one of its important mechanisms for the treatment of chronic heart failure. But the specific control process still needs in-depth study.

Data Availability

The datasets used and/or analyzed during the current study are available from the corresponding author upon reasonable request.

Disclosure

Zelin Xu and Qingyang Chen are co-first authors.

Conflicts of Interest

The authors declare that they have no conflicts of interest.

Acknowledgments

This work was supported by the National Youth Foundation of NSFC (no. 81704061), the Natural Science Foundation of Hunan Province (no. 2019JJ50465), the Open Fund Project of Hunan Province’s “Domestic First-Class Cultivation Discipline” for Integrated Traditional Chinese and Western Medicine (nos. 2018ZYX42 and 2019ZXYH12), the Hunan Science and Technology Talent Support Project (2020TJ-N01), and the 2019 Hunan University of Traditional Chinese Medicine School-Level Scientific Research Foundation (2019XJJ046).

References

[1] E. Revuelta-López, J. Lupón, A. Lax, D. Pascual-Figal, and A. Bayés-Genís, “Differences in the interleukin-1β/soluble ST2 interplay between acute and chronic heart failure,” Journal of Cardiovascular Translational Research, vol. 13, no. 5, pp. 864–866, 2020.
[2] A. Palazzuoli, C. Lombardi, G. Ruocco et al., “Chronic kidney disease and worsening renal function in acute heart failure: different phenotypes with similar prognostic impact?” European Heart Journal: Acute Cardiovascular Care, vol. 5, no. 8, pp. 534–548, 2016.
[3] S. A. Hunt, “ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College Cardiology/America Heart
Association task force on practice guidelines,” *Circulation*, vol. 112, no. 12, pp. 154–235, 2005.

[4] X. Chen, H. Cai, Q. Chen et al., “Effects of Wenyangzhenshuai Granule on ERK1/2 and ERK5 activity in the myocardial tissue in a rabbit model of adriamycin-induced chronic heart failure,” *International Journal of Clinical and Experimental Medicine*, vol. 8, no. 11, pp. 20732–20741, 2015.

[5] J.-U. Hartmann, D. Bräuer-Hartmann, M. Kardosova et al., “MicroRNA-143 targets ERK5 in granulopoiesis and predicts outcome of patients with acute myeloid leukemia,” *Cell Death & Disease*, vol. 9, no. 8, p. 814, 2018.

[6] N. I. Viana, S. T. Reis, N. G. Dip et al., “MicroRNAs 143 and 145 may be involved in benign prostatic hyperplasia pathogenesis through regulation of target genes and proteins,” *The International Journal of Biological Markers*, vol. 29, no. 3, pp. e246–52, 2014.

[7] F. Zheng, J. Zhang, S. Luo et al., “miR-143 is associated with proliferation and apoptosis involving ERK5 in HeLa cells,” *Oncology Letters*, vol. 12, no. 4, pp. 3021–3027, 2016.

[8] V. Khach Lai, M. Ashraf, S. Jiang, and K. Haider, “MicroRNA-143 is a critical regulator of cell cycle activity in stem cells with co-overexpression of Akt and angiopoietin-1 via transcriptional regulation of Erk5/cyclin D1 signaling,” *Cell Cycle*, vol. 11, no. 4, pp. 767–777, 2012.

[9] F. Vacante, L. Denby, J. C. Sluimer, and A. H. Baker, “The function of miR-143, miR-145 and the MiR-143 host gene in cardiovascular development and disease,” *Vascular Pharmacology*, vol. 112, pp. 24–30, 2019.

[10] L. Gao, T. Yang, J. Zhu, L. Xu, L. Su, and D. Wang, “Effect of Qiangxin Huoli decoction on rats with adriamycin-induced chronic heart failure,” *Journal of Traditional Chinese Medicine*, vol. 39, no. 1, pp. 81–88, 2019.

[11] J. P. M. Luiz, J. E. Toller-Kawahisa, P. R. Viacava et al., “MEK5/ERK5 signaling mediates IL-4-induced M2 macrophage differentiation through regulation of c-Myc expression,” *Journal of Leukocyte Biology*, vol. 108, no. 4, pp. 1215–1223, 2020.

[12] C. García-Hoz, G. Sánchez-Fernández, R. García-Escudero et al., “Protein kinase C (PKC) ζ-mediated Gaq stimulation of ERK5 protein pathway in cardiomyocytes and cardiac fibroblasts,” *Journal of Biological Chemistry*, vol. 287, no. 10, pp. 7792–7802, 2012.

[13] W. Yibin, “Mitogen-activated protein kinases in heart development and diseases,” *Circulation*, vol. 116, no. 12, pp. 1413–1423, 2007.

[14] J. Liu, Z. Xu, S. Yang et al., “Efficacy and safety of Qishen granules for chronic heart failure: a protocol for systematic review and meta-analysis,” *Medicine (Baltimore)*, vol. 99, no. 52, Article ID e23901, 2020.

[15] X. Wang, T. Tang, M. Zhai et al., “Ling-Gui-Zhu-Gan decoction protects H9c2 cells against H2O2-induced oxidative injury via regulation of the Nrf2/Keap1/HO-1 signaling pathway,” *Evid Based Complement Alternat Med*, vol. 2020, Article ID 8860603, 2020.

[16] S. Noguchi, Y. Yasui, J. Iwasaki et al., “Replacement treatment with microRNA-143 and -145 induces synergistic inhibition of the growth of human bladder cancer cells by regulating PI3K/Akt and MAPK signaling pathways,” *Cancer Letters*, vol. 328, no. 2, pp. 353–361, 2013.

[17] B. N. Davis-Dusenberg, M. C. Chan, K. E. Reno et al., “Down-regulation of krüppel-like factor-4 (KLF4) by MicroRNA-143/145 is critical for modulation of vascular smooth muscle cell phenotype by transforming growth factor-β and bone morphogenetic protein 4,” *Journal of Biological Chemistry*, vol. 286, no. 32, pp. 28097–28110, 2011.

[18] K. Sun, J. Yang, and D. K. Shen, “Clinical observation on treatment of primary knee osteoarthritis of liver and kidney deficiency type with Aconite cake-separated moxibustion,” *Zhongguo Zhen Jiu*, vol. 28, no. 2, pp. 87–90, 2008.

[19] S. Sang, H. D. Sook, F. S. Tareq, and Y. Fasina, “Precision research on ginger: the type of ginger matters,” *Journal of Agricultural and Food Chemistry*, vol. 68, no. 32, pp. 8517–8523, 2020.

[20] G. Pastorino, L. Cornara, S. Soares, F. Rodrigues, and M. B. P. P. Oliveira, “Liquorice (Glycyrrhiza glabra): a phytochemical and pharmacological review,” *Phytotherapy Research*, vol. 32, no. 12, pp. 2323–2339, 2018.